Effects of oral bexarotene (Targretin®) on the minimal erythema dose for broadspectrum UVB light

Skin Pharmacology and Applied Skin Physiology

Volumn 16, Issue 4, 2003, Pages 237-241

  Smit, J V ^a   De Jong, E M G J ^a   Van De Kerkhof, P C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bexarotene; Cutaneous T cell lymphoma; Erythema; LGD 1069; Minimal erythema dose; Psoriasis; Rexinoid; RXR; Targretin; UVB

Indexed keywords

BEXAROTENE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERYTHEMA; HUMAN; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS; RADIATION DOSE; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTICARCINOGENIC AGENTS; DOSE-RESPONSE RELATIONSHIP, RADIATION; ERYTHEMA; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; SKIN; TETRAHYDRONAPHTHALENES; TRANSCRIPTION FACTORS; ULTRAVIOLET RAYS;

EID: 0037678979     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000070846     Document Type: Article

References (16)

1. Boehm MF, Zhang L, Badea BA, White SK, Mais DE, Berger E, Suto CM, Goldman ME, Heyman RA: Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. J Med Chem 1994;37:2930-2941.
2. Mangelsdorf DJ, Umesono K, Kliewer SA, Borgmeyer U, Ong ES, Evans RM: A direct repeat in the cellular retinol-binding protein type II gene confers differential regulation by RXR and RAR. Cell 1991;66:555-561.
3. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. J Clin Oncol 2001;19:2456-2471.
4. Smit JV, de Jong EMGJ, van Hooijdonk CAEM, Kooijmans-Otero ME, de Jongh GJ, Lambert J, Roseeuw DI, De Weert J, Stevens VJ, van de Kerkhof PCM: A multicentre phase II clinical and immunohistochemical trial of systemic bexarotene (Targretin®) in psoriasis. J Invest Dermatol 2000;114:776.
5. Iest J, Boer J: Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol 1989;120:665-670.
6. Lebwohl M: Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999;41:22-24.
7. Lowe NJ, Prystowsky JH, Bourget T, Edelstein J, Nychay S, Armstrong R: Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol 1991;24:591-594.
8. Tanew A, Guggenbichler A, Honigsmann H, Geiger JM, Fritsch P: Photochemotherapy for severe psoriasis without or in combination with acitretin: A randomized, double-blind comparison study. J Am Acad Dermatol 1991;25:682-684.
9. Ferguson J, Johnson BE: Photosensitivity due to retinoids: Clinical and laboratory studies. Br J Dermatol 1986;115:275-283.
10. Diffey BL, Spiro JG, Hindson TC: Photosensitivity studies and isotretinoin therapy. J Am Acad Dermatol 1985;12:119-121.
11. Madhu P, Nghiem P, Fitzpatrick T: Acute and chronic effects of the sun; in Freedberg I, Eisen A, Wolff K, Austen K, Goldsmith L, Katz S (eds): Fitzpatricks's Dermatology in General Medicine, ed 5. New York, McGraw-Hill, 1999, p 1606.
12. Grekin RC, Ellis CN, Voorhees JJ: Retinoids in the treatment of psoriasis. Monotherapy and combination. Dermatol Clin 1984;2:439.
13. Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H, Exner JH: Isotretinoin therapy for acne: Results of a multicenter dose-response study. J Am Acad Dermatol 1984;10:490-496.
14. Smit JV, de Jong EM, de Jongh GJ, van de Kerkhof PC: Topical all-trans retinoic acid does not influence minimal erythema doses for UVB light in normal skin. Acta Derm Venereol 2000;80:66-67.
15. Juhlin L, Shroot B: Intensity and area increase of UVB-induced erythema: Two variables used for studies of the influence of topically applied drugs. Acta Derm Venereol 1993;73:273-275.
16. Meunier L, Voorhees JJ, Cooper KD: In vivo retinoic acid modulates expression of the class II major his-tocompatibility complex and function of antigen-presenting macrophages and keratinocytes in ultraviolet-exposed human skin. J Invest Dermatol 1996;106:1042-1046.